| 1 | **Title** |
|---|---|

2   **Pathogenesis of HIV-1 and *Mycobacterium tuberculosis* co-infection**

| 3 | **Authors** |
|---|---|

4   Lucy CK Bell and Mahdad Noursadeghi

| 5 | **Author affiliations** |
|---|---|

6   Division of Infection & Immunity, Cruciform Building, University College London, WC1E 6BT, London, UK

7   Correspondence to M.N. **m.noursadeghi@ucl.ac.uk**

## 8 Glossary

| Term | Definition |
|---|---|
| **Acid-fast bacilli (AFB)** | Bacteria which are resistant to decolourisation during laboratory staining procedures, which is a recognised property of *Mycobacteria*. This arises due to the high mycolic acid content of the bacterial cell wall. Several diagnostic tests for TB rely on this property, including Ziehl-Neelsen staining. |
| **Bacillary load** | The measurable quantity of bacteria within a host organism or sample. |
| **Efferocytosis** | The process by which dead or dying cells are cleared by phagocytosis. |
| **Extra-pulmonary** | Anatomical locations beyond the thoracic cavity or lung. |
| **Granulomatous pathology** | Chronic inflammatory foci within tissues, primarily made up of a core of activated macrophages surrounded by CD4$^+$ T cells. |
| **Giant cells** | Multinucleated cells derived from macrophages, typically found within granulomatous inflammation. |
| **HIV-1 long terminal repeat** | Repetitive non-coding sequences at each end of the HIV-1 proviral DNA, which are formed during reverse transcription and play important roles in integration and regulation of viral gene expression. |
| **Immunoregulation** | Mechanisms by which the immune system self-regulates via negative feedback loops, e.g. the production of immunosuppressive cytokines. |
| **Independent risk factor** | A variable that improves the prediction of outcome in a statistical model which already includes other variables. |
| **Inflammasome** | Multimeric molecular complexes formed during innate immune signalling which activate caspase enzymes, control maturation of the pro-inflammatory cytokines IL-1β and IL-18, and may lead to cell death via pyroptosis. |
| **Immunosenesence** | The observable decline in immune function associated with ageing. |
| **Immunodominant** | The antigenic epitopes most commonly targeted by the adaptive immune response. |
| **Lung apices** | The upper lobe of each lung. |
| **Mycobacteraemia** | Circulation of mycobacteria in the bloodstream, identified on culture of blood. |
| **Necrotic granuloma** | Granulomatous inflammation with a core of dead cells. |
| **Phagosome** | A cytoplasmic vesicle formed as a result of the cellular uptake of particles >0.75μm in diameter. |
| **Pleural effusion** | An accumulation of fluid in the pleural cavity, the anatomical compartment which surrounds the lungs. This can arise due to a range of causes, one of which is infections such as TB. |

| | |
|---|---|
| **Pro-inflammatory cytokines** | Extracellular signalling molecules secreted chiefly by immune cells, which specific cell-surface receptors to trigger inflammatory processes. |
| **Pulmonary cavitation** | Formation of large airspaces in the lung parenchyma due to tissue destruction. |
| **Pyroptosis** | A specific cell death pathway triggered activation of caspase 1. |
| **Resting T cells** | T cells which have not been activated by binding of their cognate antigen to the T cell receptor or stimulation by mitogens. |
| **Quasispecies** | A genetically heterogenous population arising from a process of mutation and selection. |
| **Sentinel cell** | Tissue resident cell that initiates a host immune response. |
| **Serodiscordant couples** | A sexual partnership in which one partner is HIV-1 infected and the other is not. |
| **Sympatric speciation** | The evolutionary process by which one species adapts to another with which it overlaps geographically. |
| **Tuberculin skin test** | Intradermal injection of a standardised preparation of purified protein derivative of killed and homogenised *M. tuberculosis*. |
| **Th17 cells** | CD4 positive T helper cell subset that produces interleukin (IL) 17 on stimulation, which in turn has a canonical role in augmenting neutrophil responses to infection. |
| **Viral rebound** | Development of a detectable plasma viral load in a HIV-1 positive individual following a period of virological suppression, typically associated with an interruption in ART or the development of drug resistance. |

9

## Abstract

Co-infection with *Mycobacterium tuberculosis* is the leading cause of death in HIV-1 infected individuals. It has long been known that HIV-1 infection alters the course of *M. tuberculosis* infection and substantially increases the risk of active tuberculosis (TB). It has also become clear that TB increases levels of HIV-1 replication, propagation and genetic diversity. Therefore, co-infection provides reciprocal advantages to both pathogens. In this Review, we describe the epidemiological associations between the two pathogens, selected interactions of each pathogen with the host and our current understanding of how they affect the pathogenesis of TB and HIV-1/AIDS in co-infected individuals. We evaluate the mechanisms and consequences of HIV-1 depletion of T cells on immune responses to *M. tuberculosis*. We also discuss the effect of HIV-1 infection on the control of *M. tuberculosis* by macrophages through phagocytosis, autophagy and cell death, and we propose models by which dysregulated inflammatory responses drive the pathogenesis of TB and HIV-1/AIDS.

## Key points

− There were 1.14 million new cases of HIV-1/TB co-infection and 400,000 deaths that were attributed to co-infection in 2015.

− The risk of TB increases by 2-5 fold in early HIV-1 infection and by more than 20-fold in advanced HIV-1 disease. Approximately 4-fold increased risk of TB persists in HIV-1 infected patients treated with antiretroviral therapy.

− HIV-1 infects CD4$^+$ T cells and macrophages. *Mycobacterium tuberculosis* primarily infects macrophages, which require CD4$^+$ T cells to augment intracellular clearance of microbial pathogens. Hence the depletion of CD4$^+$ T cells that is associated with HIV-1 infection is thought to have a major role in the increased risk of TB in HIV-1 infected people.

− Co-infection of HIV-1 and *M. tuberculosis* at the level of individual macrophages may also occur, but has not been demonstrated in vivo. This is important because experimental models show that HIV-1 infection of macrophages can attenuate phagocytosis and intracellular killing by the autophagy pathway.

− Progressive HIV-1 disease and TB are both characterised by chronic inflammation driven by the failure to clear either pathogen. The chronic nature of these responses may undermine host protection by promoting an immunoregulatory phenotype that is characterised by attenuated T cell responses.

− Advanced HIV-1 infection is associated with reduced immunopathology of TB co-infection, but the introduction of antiretroviral therapy can exacerbate the immunopathology of TB, giving rise to immune reconstitution inflammatory syndrome (IRIS). This reflects recovery of innate immune inflammatory responses to *M. tuberculosis*, which may be exacerbated by the recirculation of *M. tuberculosis* reactive T cells and failure of the normal homeostatic control of inflammatory responses.

− The proinflammatory response to *M. tuberculosis* may exacerbate HIV-1/AIDS disease progression by increasing virus propagation through increased transcription and cell-cell transmission.

## Introduction

The retrovirus HIV-1, which causes Acquired Immunodeficiency Syndrome (AIDS), transmitted to humans from primates in the 20th century[1]. The causative agent of tuberculosis (TB), *Mycobacterium tuberculosis*, is an unencapsulated acid-fast bacillus which has been a pathogen of humans for millennia[2]. HIV/AIDS and TB are each among the 10 leading causes of death world-wide. The interaction between these two pathogens substantially contributes to this high incidence of mortality. Estimates for the incidence of HIV-1 and *M. tuberculosis* infection in 2015 highlights the scale of these epidemics (**Table 1**)[3,4]. The geographical convergence of the HIV/TB 'syndemics' in Africa and in Eastern Europe, as well as the demographic convergence in particular at-risk groups, such as prisoners[5] and miners in Southern Africa[6], further exacerbate the burden of co-infection morbidity and mortality. The impact of TB is also increasing with the emergence of multi-drug resistant (MDR)-TB (**Table 1**), for which HIV-1 is an independent risk factor[7]. Moreover, the rates of undiagnosed TB in HIV-1 positive individuals as revealed by post-mortem studies[8], suggest that the disease burden that is associated with co-infection has been underestimated.

An increased risk of TB throughout the course of HIV-1 disease has been established through epidemiological studies[9,10] (**Figure 1a**). HIV-1 co-infection also influences the clinical phenotype of TB. HIV-1 positive patients with CD4[+] T cell counts in the normal range present with classic symptoms of pulmonary TB, but disease that is restricted to the lung apices is less frequent, whereas pleural effusions and lymph node disease are more likely[11]. In advanced AIDS, *M. tuberculosis* frequently causes disseminated extra-pulmonary disease and mycobacteraemia[12,13].

TB may also exacerbate HIV-1 disease and AIDS progression (**Figure 1b**). Active TB is associated with higher HIV-1 viral loads in the blood[14] and cerebrospinal fluid (CSF)[15], and an increased genetic heterogeneity of the viral quasispecies[16]. This is likely to be driven by increases in HIV-1 replication at the site of co-infection[17,18]. In addition, *M. tuberculosis* co-infection may contribute to higher levels of systemic immune activation that is associated with HIV-1 disease progression[19,20], even in the context of latent TB infection (LTBI)[21]. The importance of these phenotypes in driving HIV-1 disease progression is unknown, but based on our understanding of how high viral loads[22] and immune activation[23] can drive immunosuppression, co-infection with *M. tuberculosis* may accelerate AIDS progression. Accordingly, TB has been associated with an increased incidence of additional opportunistic infections[24], and may be an independent risk factor for progression to AIDS[25]. This hypothesis is supported by the observation that an episode of successfully treated TB is associated with a four-fold increase in all-cause mortality associated with HIV HIV[26].

Understanding the mechanisms that underpin HIV-1 and TB co-infection is paramount to identifying the best approaches to overcome the global burden of disease that is caused by these pathogens. In this Review, we describe the specific host-pathogen interactions which have emerged as common features of both organisms. In particular, their ability to infect macrophages, induce type 1 interferon (IFN) responses and the role of chronic or dysregulated inflammation in the pathogenesis of disease. We then describe our current understanding of the mechanisms by which each organisminfluences the pathogenesis of the co-infecting pathogen, and consider the future challenges for research in this field.

82 **HIV-1 infection**

83 **Cellular targets of HIV-1**

84 CD4[+] T cells are considered the primary target cells for HIV-1. Macrophages are also infected by HIV-1 and

85 may have an important role in HIV/AIDS pathogenesis. CD4[+] T cells and macrophages are also thought to be

86 crucial for host defence against *M. tuberculosis*[27] (Figure 2). Given that macrophages are the primary

87 intracellular niche for *M. tuberculosis*, their permissivity to HIV-1 raises the possibility that the two pathogens

88 can co-infect individual cells. HIV-1 infection of monocyte-derived macrophages *in vitro* is well described

89 despite the fact that macrophages express SAMHD1, an endonuclease that is active in non-dividing cells.

90 SAMHD1 has dNTPase activity and therefore depletes the cell of nucleotides that are required for DNA

91 synthesis, thereby restricting HIV-1 reverse transcription[28]. The simian immunodeficiency virus (SIV)

92 accessory protein Vpx (which is absent in HIV-1) degrades SAMHD1 and makes human myeloid cells more

93 permissive to retroviral infection. Interestingly, Vpx deficient SIV still infects myeloid cellsin non-human

94 primates[29], suggesting that Vpx is not necessary for infection of myeloid cells in vivo.  Nonetheless, the

95 observation that HIV-1 has not evolved to counteract SAMHD1 restriction had led to the hypothesis that HIV-1

96 infection of macrophages does not occur in vivo. However, sub-populations of human macrophages enter a

97 G1-like state in which SAMHD1 activity is downregulated, making the cells substantially more permissive to

98 HIV-1[30]. These data provide a mechanism by which a retrovirus that cannot counteract SAMHD1 restriction is

99 able to infect non-dividing myeloid cells. A subset of human alveolar macrophages that are infected with HIV-

100 1 in vivo, have been identified by RNA fluorescence in situ hybridisation, suggesting that the virus in these

101 cells may be transcriptionally active[31]. Furthermore, sustained HIV-1 replication in the absence of T cells has

102 been demonstrated in non-human primates and in humanised mouse models[32,33].

103 Long-lived memory CD4[+] T cells are thought to be the dominant cell type in which HIV-1 can establish latency

104 and evade clearance by antiretroviral therapy (ART). Proviral DNA can also be detected in alveolar

105 macrophages in patients on ART[34]. Moreover, viral rebound following ART treatment interruption has been

106 described in humanized myeloid-only mice, indicating that macrophages may also act as a long term viral

107 reservoir[35]. Importantly, the viral reservoir during ART is not completely latent, but exhibits low levels of HIV-1

108 replication[36]. This may occur in 'sanctuary sites' where drugs do not reach sufficient concentrations. Lymphoid

109 tissue has been proposed as one such site[37,38]. Macrophage populations within the central nervous system

110 may be another[39]. Therefore, HIV-1 replication may still influence *M. tuberculosis* infection even in patients

111 receiving effective ART, particularly if this occurs within macrophages.

112 **Induction and evasion of type 1 IFN responses**

113 Type 1 IFNs represent the canonical innate immune response to viral infections[40]. This response coincides

114 with the peak in viraemia that follows primary HIV-1 infection[41]. In various models, HIV-1 has been shown to

115 activate innate IFN responses through pattern recognition receptors (PRRs), including toll-like receptor (TLR)-

116 7[42], RIG-I[43] and DDX3[44] RNA sensors, as well as cGAS[45], PQBP1[46] and IFI16[47] DNA sensors. This response

117 is thought to contribute to suppression of primary HIV-1 viraemia[48], albeit without achieving complete

118 suppression owing to the range of counter measures that are employed by viruses to overcome IFN-inducible

119 antiviral host proteins[49]. Interestingly, HIV-1 infection and replication in macrophages, representing key tissue

120 resident innate immune sentinel cells, fails to induce innate IFN responses as a result of interactions between

121 the viral capsid and host proteins that shield the nascent DNA products of viral reverse transcription from host

122 DNA sensors[50]. Macrophages successfully restrict HIV-1 in response to type 1 IFN[51]. Therefore, the ability of

123  the virus to evade innate immune detection in macrophages may have an important role in establishing

124  persistent HIV-1 infection.

125  **HIV-1 infection as a chronic inflammatory disease**

126  HIV-1 infection is increasingly considered a chronic inflammatory disease that leads to immunodeficiency.

127  Inflammatory markers are elevated throughout the asymptomatic phase of infection[52] and correlate with the

128  rate of progression to AIDS[23]. The same phenotype is not evident in non-pathogenic SIV infection of

129  non-human primates and in HIV-1 infected children who do not progress to immunodeficiency[53].

130  Several mechanisms are thought to lead to the chronic immune activation that is associated with HIV-1

131  infection[52]. Chief among these is the translocation of microbial products from the gastrointestinal lumen into

132  the bloodstream, following massive T cell depletion in gastrointestinal-associated lymphoid tissue (GALT)

133  during primary HIV-1 infection. This is thought to be caused by lytic infection of GALT Th17 cells[54], which are

134  particularly permissive to retroviral infection[55]. Non-productive HIV-1 infection of resting T cells by cell-cell

135  spread in lymphoid tissue may also contribute to T cell depletion and immune activation. In this model,

136  incomplete DNA products of reverse transcription are recognised by the cytosolic DNA sensor IFI16, leading

137  toactivation of the inflammasome, leading to cell death by pyroptosis and the release of proinflammatory

138  IL1β[56,57], thereby linking CD4$^+$ T cell depletion and chronic inflammation[58,59]. In contrast to this inflammatory

139  mechanism of T cell death, HIV-1 proviral DNA integration may activate DNA damage pathways that can cause

140  T cell apoptosis[60]. Chronic immune activation may also lead to premature immune senescence or

141  compensatory immunoregulation[61–63]. Research efforts have focussed on the role of chronic type 1 IFN

142  responses in persistent HIV-1 infection. In a non-human primate model of pathogenic HIV-1 infection, chronic

143  IFN stimulation caused IFN desensitisation and consequently, reduced expression of IFN-dependent antiviral

144  factors, leading to increased viral replication and further T cell depletion[48].

145  The strong link between HIV-1 infection and chronic inflammation raises the question of whether the virus

146  gains an advantage by driving this phenotype. One which, co-infection with *M. tuberculosis* may be expected

147  to compound as it also induces chronic inflammation. Inflammatory signalling may benefit HIV-1 by directly

148  stimulating viral replication (discussed below). In addition, the recruitment of leukocytes could potentially

149  provide HIV-1 with a source of target cells to infect. This may be particularly important as HIV-1 infects new

150  cells most efficiently by direct cell-cell transmission via a 'virological synapse'  actively orchestrated by the

151  virus[64]. Cell-cell transmission also shields the virus from neutralising antibodies[65], leads to more rapid viral

152  gene expression[66] and enables the virus to overcome cell tropism barriers, such as infection of macrophages

153  by non-macrophage tropic viruses[67].

154  [Au: Please insert a brief summary paragraph (2-3 sentences) to conclude this section and to refocus the

155  reader back to HIV/TB co-infection.]

156

157  **M. tuberculosis infection**

158  **Infection of macrophages**

159  *M. tuberculosis* is a facultative intracellular pathogen of macrophages. Once inside, *M. tuberculosis* quickly

160  adapts to the environment within the phagosome through transcriptional reprogramming in order to upregulate

161  iron scavenging mechanisms, switch to anaerobic respiratory pathways, and to use cholesterol as a carbon

162  source and aspartate as a nitrogen source[68]. Within macrophages, *M. tuberculosis*-containing phagosomes

163    fail to undergo the normal process of maturation and acidification that is associated with phagolysosomal fusion

164    and by which phagosomal cargo is usually degraded. Multiple *M. tuberculosis* virulence factors are thought to

165    contribute to this phenotype[69].

166    Macrophage cell death is a key feature of granulomatous pathology in TB. Central to this process is the

167    bacterial ESX-1 secretion system and the secreted effector molecule ESAT6. These are encoded by the RD1

168    locus which is deleted in the live attenuated *Mycobacterium bovis*, bacille Calmette–Guérin (BCG) vaccine.

169    ESX-1 is required for *M. tuberculosis* to escape from phagosomes into the host cell cytoplasm, and for

170    triggering cell death pathways[70]. ESAT6 can also trigger macrophage cell death through apoptosis[71]. In

171    addition, ESAT6 has been reported to activate the inflammasome[72], suggesting that *M. tuberculosis* may cause

172    cell death through inflammasome/caspase 1-mediated pyroptosis. The triggering of cell death promotes

173    bacterial dissemination through efferocytosis[73] and by releasing bacteria into the extracellular space for onward

174    transmission to new hosts.

175    **Induction of innate immune type 1 IFN responses**

176    Mycobacterial lipids, lipoproteins and nucleic acids trigger a range of innate immune responses when they are

177    sensed by host PRRs within macrophages[74,75]. These responses are thought to be crucial for further immune

178    cell recruitment and for the production of antimicrobial peptides[76]. Innate immune responses to *M. tuberculosis*

179    include type 1 IFN responses that have conventionally been associated with antiviral responses[77]. The

180    observation that type 1 IFNs are immunosuppressive in chronic viral infections has led to studies to determine

181    whether type 1 IFNs counteract immunoprotective IFN$\gamma$-dependent or IL1$\beta$-dependent mechanisms of

182    *M. tuberculosis* clearance[78]. Induction of type 1 IFN responses is principally mediated through the recognition

183    of *M. tuberculosis* nucleic acids by the cytosolic DNA sensor cGAS[75]. This is dependent on ESX-1-mediated

184    *M. tuberculosis* phagosomal escape, which also drives inflammasome maturation of IL1$\beta$ [79]. Interestingly, the

185    levels of effector molecules (ESAT6) that are secreted by the ESX-1 system determines the outcome of host

186    cellular responses polarised towards either type 1 IFNs or IL1$\beta$). *M. tuberculosis* strains that are more virulent

187    have been found to produce more ESAT6 and more type 1 IFNs[80].

188    **Chronic inflammation to promote transmission**

189    Similar to HIV-1 infection, chronic inflammation is the hallmark of TB pathology. Immunopathogenesis may

190    even be more important in this case because, unlike HIV-1, *M. tuberculosis* is an obligate pathogen. Its ability

191    to escape the intracellular niche, cause pulmonary cavitation and induce coughing through chronic

192    inflammation within airways, are necessary for its dispersal between individuals. Matrix metalloproteinase

193    (MMP)-1 has a crucial role in pulmonary cavitation that is associated with *M. tuberculosis* infection[81]. This

194    protein belongs to a family of host proteinases that degrade the extracellular matrix. MMPs are produced by

195    macrophages, epithelial cells and fibroblasts in response to pro-inflammatory cytokines. In this context, chronic

196    pro-inflammatory T cells may contribute to the pathology in response to persistent *M. tuberculosis.* The

197    observation that virulent *M. tuberculosis* strains have highly conserved immunodominant T cell epitopes

198    suggests that *M. tuberculosis* does not rely on antigenic variation to evade protective immunity[82,83]. In addition,

199    it raises the possibility that the conservation of these immunodominant responses may be beneficial to the

200    pathogen. Thereby, *M. tuberculosis* may commandeer T cell responses to promote immunopathology and

201    consequently, its transmission.

## HIV/TB co-infection

### HIV-1 depletion of *M. tuberculosis* reactive T cells

Notwithstanding the hypothesis presented above that T cell responses in TB may contribute to pathogenesis of disease, they have long been thought to have an important role in immunological protection against *M. tuberculosis* by promoting intracellular bacterial killing or restriction (Figure 2). Genetic deficiencies in IL12 signalling (which is required for Th1 cell differentiation), or IFNγ signalling (representing the canonical product of Th1 responses), give rise to Mendelian susceptibility to mycobacterial disease (MSMD)[84]. HIV-1 co-infection further highlights the importance of T cell mediated immunity. Substantially increased risk of TB and its extrapulmonary dissemination is strongly correlated with CD4+ T cell depletion in HIV-1 infected individuals. T cell depletion is evident in peripheral blood, in the respiratory tract and at the site of tuberculin skin test (TST) challenge[85–87]. Assuming that CD4+ T cell protection against *M. tuberculosis* is conferred by the pro-inflammatory cytokines that they produce, it is notable that the proportions of polyfunctional *M. tuberculosis* reactive T cells, which produce the pro-inflammatory cytokines IFNγ, tumour necrosis factor (TNF) and interleukin (IL)2 are also depleted in HIV-1 infected individuals[86]. Hence, HIV-1 depletes T cell populations that are likely to be functionally important for protection against TB. Transcriptional profiling of biopsies taken from the site of the TST challenge in humans confirmed that T cell recruitment and IFNγ activity were both substantially reduced in HIV-1/TB co-infected patients, with blood CD4+ T cell counts of <200 per mL, indicative of advanced HIV-1 disease[85].

HIV-1 infected T cells may also contribute to the increased risk of TB in early HIV-1 disease before substantial depletion of peripheral blood CD4 counts[87]. HIV-1 DNA was detected more frequently in *M. tuberculosis* specific T cells. These T cells produced high levels of IL2 which made them more permissive to HIV-1 infection. In comparison to the total memory T cell population or memory T cells that specifically recognise human cytomegalovirus, *M. tuberculosis* specific T cells were preferentially depleted in early HIV-1 infection. Taken together these data suggest that the depletion of these cells may be a direct result of HIV-1 infection. Transcriptional profiling of the TST challenge site biopsies in HIV-1/TB co-infected patients with blood CD4+ T cell counts >200 /mL also revealed less T cell recruitment at the site of the antigenic challenge, compared to HIV-1 negative patients with active TB[85]. However, the functional significance of the reduced T cell recruitment observed in this study is currently unknown, as comparable levels of IFNγ inducible gene expression were found in the HIV-1 positive and negative groups. Hence, IFNγ activity as a surrogate of robust CD4 T cell responses to mycobacterial antigens was preserved in early HIV-1 disease, despite previous reports of preferential depletion of *M. tuberculosis* specific T cells. These data suggest that increased risk of TB in HIV-1 infected patients is not solely mediated by T cell depletion.

Of the other T cell populations that may contribute to HIV-1-associated TB, Th17 and Th22 cells are the most plausible candidates. A functional role for these T cell populations in immunological protection against TB is primarily based on data obtained from experiments in mice and by their role in the recruitment of phagocytic cells including macrophages[88–90]. The depletion of these T cell subtypes during primary HIV-1 infection[54,91] may therefore contribute to differences in the immune response to *M. tuberculosis* in HIV-1 co-infected patients compared to HIV negative patients. Another T cell population that becomes depleted in HIV-1 infection are mucosal associated invariant T (MAIT) cells[92]. These are CD8+ innate lymphoid cells which recognise bacterial metabolites of vitamin B that are presented by a non-polymorphic MHC-like molecule, MR1[92]. MAIT cells are activated by *M. tuberculosis* and are enriched at the site of TB disease[93]. Therefore, their depletion in HIV-1

243    infection may attenuate a component of host immune responses to *M. tuberculosis*. MAIT cells are not infected

244    by HIV-1. Their depletion is thought to be caused indirectly by immune activation. Importantly, by comparison

245    to the general population, the risk of active TB remains higher in HIV-1 infected patients even after becoming

246    established on effective ART[94]. In this context, the failure of ART to restore the T cell repertoire, including MAIT

247    cells[95,96], may also be a significant factor in the persistently elevated risk of TB.

**HIV-1 inhibition of phagocytosis and autophagy in macrophages**

249    *M. tuberculosis* has evolved to survive and grow within macrophages. Nonetheless, *M. tuberculosis*

250    phagocytosis by macrophages is thought to restrict mycobacterial growth. The best evidence for this is comes

251    from experiments in the zebrafish *Mycobacterium marinum* model in which bacillary uptake by macrophages

252    is elegantly visualised. In this model, macrophage depletion, delayed macrophage recruitment or necrotic

253    macrophage cell death are all associated with increased microbial burden[73,97,98]. Once the bacteria are

254    phagocytosed, phagolysosomal fusion that would lead to bacterial killing is inhibited by *M. tuberculosis*. This

255    may be overcome by the autophagy pathway[99,100], and by inducible production of bacteriocidal nitric oxide or

256    a range of antimicrobial peptides, all of which are generally upregulated by the action of IFN$\gamma$.

257    HIV-1 infection has been reported to inhibit macrophage phagocytosis dependent on diverse cell surface

258    receptors and mediated by HIV-1 infection of the affected cell[101]. In this study, the HIV-1 accessory protein Nef

259    was found to be both necessary and sufficient to inhibit phagocytosis by directly interacting with adapter protein

260    AP-1 to inhibit the recruitment of recycling endosomes that are required for phagosome biogenesis[101]. It is also

261    possible that these effects may be mediated indirectly by the action of circulating virus-free accessory proteins

262    on uninfected macrophages, which can be detected *in vivo*[102,103]. Moreover, impaired phagocytosis has also

263    been observed in HIV-infected alveolar macrophages *ex vivo*[31]. Interestingly, HIV-1 Nef also inhibits the

264    autophagy pathway by blocking the maturation of autophagosomes through a direct interaction with the

265    autophagy regulator, Beclin-1[104]. This inhibition was found to protect nascent virion assembly from autophagic

266    degradation. Consistent with these effects of HIV-1 infection on phagocytosis and autophagy (Figure 2), HIV-1

267    co-infection in macrophages that are infected with *M. tuberculosis* has been associated with increased

268    mycobacterial growth[105]. Interestingly, however, vitamin D treatment of co-infected macrophages was reported

269    to restrict both *M. tuberculosis* and HIV-1 replication by an autophagy-dependent mechanism, suggesting that

270    the inhibition of autophagy by HIV-1 is easily overcome by the action of vitamin D[106]. Vitamin D deficiency is

271    undoubtedly prevalent amongst populations at greatest risk of co-infection[107]. Therefore, if HIV-1 inhibition of

272    autophagy is an important determinant for increased risk of TB, vitamin D supplementation may substantially

273    reduce the incidence of TB disease in HIV-1 infected patients while at the same time supporting immune

274    control of the virus. However, this hypothesis has yet to be tested in clinical trials.

**Macrophage cell death and tissue necrosis in HIV/TB co-infection**

276    HIV-1 does not cause macrophage cell death[51]. A number of reports suggest that HIV-1 proteins reduce

277    *M. tuberculosis*-associated macrophage apoptosis; potentially by HIV-1 Nef inhibition of TNF responses to

278    *M. tuberculosis*[108–110]. Ccellular apoptosis has been considered as a mechanism for limiting intracellular

279    *M. tuberculosis* growth. Therefore, by inhibiting apoptosis, HIV-1 infection may compromise *M. tuberculosis*

280    restriction. However, live cell imaging data has recently contradicted this hypothesis by demonstrating that cell

281    death is associated with *M. tuberculosis* growth rather than restriction[111]. A key observation in HIV-1 infected

282    patients with pulmonary TB is the presence of fewer necrotic granuloma and less pulmonary cavitation.

283    Interestingly, in active TB MMP1 levels are significantly lower in respiratory tract samples from HIV-1 infected

284 patients with severe CD4+ T cell depletion, compared to HIV-1 negative patients[112]. These observations have

285 largely supported the hypothesis that T cell responses to *M. tuberculosis* contribute substantially to cellular

286 necrosis and tissue damage. In agreement with this cellular necrosis and tissue damage are reduced in

287 patients with AIDS, but enhanced host cell viability in advanced HIV-1 disease does not achieve better

288 *M. tuberculosis* control. Consistent with the reduction in pulmonary cavitation, HIV-1 co-infected patients may

289 transmit less *M. tuberculosis*[113]. Nonetheless, at the population level, an increased incidence of active TB in

290 HIV-1 infected patients  ultimately promotes the onward transmission of *M. tuberculosis*.

291 **Immunopathology of *M. tuberculosis* in HIV-1 infected patients**

292 The most direct evidence to support the hypothesis that there is a reduction of *M. tuberculosis*

293 immunopathology in patients with AIDS, is the phenomenon of TB immune reconstitution inflammatory

294 response syndrome (TB-IRIS). TB-IRIS is the development of increased inflammatory pathology in patients

295 following the commencement of ART, and may manifest by either a worsening of known TB disease, or

296 'unmasking' of previously asymptomatic *M. tuberculosis* infection[114]. TB-IRIS occurs in ~15% of HIV-1 infected

297 patients starting ART[115] and is most commonly found in patients with very low peripheral blood CD4+ T cell

298 counts and evidence of a high *M. tuberculosis* bacillary load before starting ART. The pathological features of

299 TB-IRIS include systemic responses such as fever and increased acute neutrophilic inflammation at the site

300 of *M. tuberculosis* infection. Comparisons of peripheral blood transcriptional profiles in cohorts of HIV/TB

301 co-infected patients with and without TB-IRIS revealed that in cases of TB-IRIS,  there were increases in the

302 expression of IFN, MyD88 and inflammasome-dependent innate immune responses[116]. These data suggest

303 that TB-IRIS may be caused by the recovery of innate immune responses to *M. tuberculosis*, and presumably

304 failure of immunoregulation that would ordinarily control pathogenic innate inflammatory responses. By

305 inference these data  suggest that HIV-1 may downregulate innate immune and immunoregulatory responses

306 to *M. tuberculosis*, as well as classical Th1 responses. With the notable exception of type 1 IFNs, the wide

307 repertoire of pro-inflammatory transcriptional innate immune responses at the site of TST challenge, were

308 found to be lower in patients with active TB and advanced HIV-1 co-infection compared to.HIV-1 negative

309 controls[85]. By contrast, patients presenting with unmasking TB-IRIS had substantially higher pro-inflammatory

310 transcriptional responses to the TST compared to HIV-1 negative patients with active TB, consistent with

311 exaggerated inflammatory responses. In this study, unmasking TB-IRIS was associated with features that are

312 associated with Th2 responses and increased granulocyte colony stimulating factor (CSF3) expression that is

313 known to augment neutrophil responses[85].

314 How HIV-1 might inhibit innate immune responses to *M. tuberculosis* remains unclear. Both pathogens can

315 infect macrophages, which are widely recognised to generate pro-inflammatory innate immune responses.

316 Attenuated innate immune responses to prototypic stimuli such as lipopolysaccharide (LPS) by alveolar

317 macrophages from HIV-infected individuals has been reported[117,118]. The HIV-1 accessory proteins Nef, Vpu

318 and Vpr have each been reported to inhibit innate immune intracellular signalling pathways[119]. Consistent with

319 these reports, HIV-1 infection of macrophages attenuated activation of the canonical NFkB pathway in

320 response to LPS[120]. However, genome-wide transcriptional responses to LPS were largely preserved. In the

321 same experimental model of macrophages that were infected with HIV-1, pro-inflammatory innate immune

322 responses to *M. tuberculosis* co-infection were also preserved[121–123]. Instead, HIV-1 infection was associated

323 with attenuated immunoregulatory IL10 expression, leading to exaggerated pro-inflammatory responses at

324 subsequent time points[121]. These data suggest that any HIV-1 associated inhibition of innate immune

325  pro-inflammatory responses to *M. tuberculosis* by HIV-1 does not arise because of co-infection at the cellular

326  level.

327  Indirect effects on macrophage innate immune responses may also result from HIV-1 modulation of T cells,

328  for example, by alterations in the cytokine milieu that acts on uninfected macrophages. Therefore, an

329  alternative hypothesis may be that pathogenic innate immune responses to *M. tuberculosis* are amplified by

330  T helper cells. In such a model, the immunopathogenesis of TB-IRIS may be driven by the recirculation of

331  *M. tuberculosis* reactive T cells, leading to the recovery of innate immune inflammatory responses and

332  compounded by high bacterial loads which have accumulated in the immunosuppressed patient providing a

333  higher dose for stimulation of innate immune responses[114]. In this context, HIV-1 attenuation of IL10 responses

334  in macrophages may represent foci of deficient immunoregulation that leads to pathological inflammation. In

335  this regard, we found that deficient IL-10 responses persist in infected macrophages in the presence of

336  antiretrovirals in vitro[121], and others have demonstrated the persistence of dysregulated phagocyte phenotypes

337  after antiretroviral treatment, such as increased TLR-2 expression[124] and a dysregulation of complement

338  pathways[125]. Hence, TB-IRIS may be caused by a combination of high bacterial burden, T cell recovery and

339  failure of immune regulation in HIV-1 infected macrophages (Figure 3). Interestingly, TST challenge

340  experiments revealed attenuated IL10 responses in HIV-1 infected patients with CD4[+] T cells >200 /mL [85].

341  Therefore, an increased risk of active TB in early HIV-1 disease may also partly reflect a propensity for

342  immunopathology as a result of inadequate IL10 regulation.

343  **Effects of TB on HIV-1 replication**

344  Increased HIV-1 viral loads in the lungs of co-infected patients with pulmonary TB is well established[17,18,126].

345  This is commonly associated with increased viral load in peripheral blood[14]. Whether the increase in circulating

346  virus arises from replication in the lung alone or is also due to increased systemic virus replication is not known.

347  As most HIV-1 replication occurs in activated T cells, their recruitment to sites of granulomatous inflammation

348  in TB may facilitate rapid virus propagation through the accumulation of tightly packed permissive cells and

349  hence cell-cell transmission. However, the host immune response to *M. tuberculosis* also increases HIV-1

350  transcription. The HIV-1 long terminal repeat (LTR) includes binding sites for several host transcription factors

351  which are activated by innate immune and cytokine signalling pathways. These include the NFκB, AP1,

352  CCAAT/enhancer binding protein (C/EBP), CREB/ATF and NFAT families of transcription factors[127]. Innate

353  immune activation by *M. tuberculosis* or mycobacterial products increased HIV-1 transcription and replication

354  in myeloid cell lines, through the action of C/EBP, NFκB and NFAT5[128–130].

355  Experimental data on the effects of *M. tuberculosis* infection on HIV-1 transcription in macrophages are

356  inconclusive. In macrophages that were infected with HIV-1, co-infection with BCG caused a dose dependent

357  suppression of virus production. This was attributed to the C/EBP binding motif in the viral LTR and associated

358  with production of a type 1 IFN inducible inhibitory isoform of C/EBPβ, leading to a model in which

359  mycobacterial induction of type 1 IFNs may restrict HIV-1 transcription[131]. These data are somewhat

360  inconsistent with the current view of ESX-1-dependent induction of type 1 IFN responses by *M. tuberculosis*[79]

361  given that BCG lacks ESX-1[132]. Interestingly, alveolar macrophages from healthy lung tissue express high

362  levels of inhibitory C/EBPβ, but this is strongly downregulated in cells that are isolated from the site of

363  pulmonary TB[131], suggesting that the pro-inflammatory milieu that are present in active TB granuloma

364  overcomes type 1 IFN-mediated inhibition of virus transcription. Direct evidence for this hypothesis was shown

365  in HIV-1 infected macrophages where co-infection with *M. tuberculosis* led to an initial decrease in HIV-1

366　transcription followed by a substantial increase[121]. The increase in virus transcription was co-incident with

367　sustained pro-inflammatory responses as a result of HIV-1 attenuation of early IL10 regulatory responses, and

368　complementation of deficient IL10 responses reversed the increase in viral transcription in *M. tuberculosis*

369　co-infected macrophages[121]. IL10 has been reported to inhibit HIV-1 transcription by STAT3-dependent

370　induction of inhibitory C/EBPβ and by inhibition of cyclin-T1 that is required for HIV-1 Tat-dependent

371　transactivation of viral transcription[133–135]. Conversely, it has long been established that some canonical

372　pro-inflammatory cytokines, for example, TNF, IL6 and IL1β, individually or synergistically upregulate HIV-1

373　transcription[136–138]. Notably, IFNγ (which is  enriched within TB granuloma) shows substantial overlap with the

374　antiviral effects of type 1 IFNs[51]. Despite this, IFNγ may still act synergistically with TNF to promote virus

375　transcription[139].

376　Increased HIV-1 replication in macrophages as a result of pro-inflammatory responses to *M. tuberculosis* may

377　also be accompanied by increased macrophage permissivity to nascent HIV-1 infection. Macrophages had

378　previously been considered as terminally differentiated cells that are unable to replicate. Mouse experiments

379　have demonstrated macrophage replication in response to inflammatory stimuli, for example modelled by

380　helminth infection[140] and for maintenance of embryologically derived resident populations[141–143]. Recent

381　findings show that polyploid giant cells within granuloma arise from macrophages that enter cell cycle but do

382　not complete cytokinesis[144]. In addition, macrophages that enter the cell cycle but arrest in a G1-like state,

383　downregulate SAMHD1 activity to allow DNA synthesis, and consequently become more permissive to HIV-1

384　by facilitating reverse transcription[30]. Taken together, the pro-inflammatory cytokine response to *M.*

385　*tuberculosis* (facilitated by HIV-1 attenuation of immune regulation), recruitment and activation of T cells, and

386　modulation of macrophage cell cycle phenotype act in concert to enhance virus replication and propagation

387　(Figure 4). Hence these co-infecting pathogens successfully cooperate to usurp host defences to their own

388　advantage.

389　**Future perspectives**

390　In resource-poor settings where the highest incidence of HIV-1 and *M. tuberculosis* co-infection is found, ART

391　has substantially reduced the incidence of co-infection and improved clinical outcomes[145]. In the pre-ART era,

392　the majority of co-infection was evident in people with advanced HIV-1 disease. Assuming that ART

393　programmes continue to grow in these settings, the majority of morbidity and mortality that is associated with

394　HIV/TB co-infection may be caused by the increased risk of TB in patients with early HIV-1 infection prior to

395　ART initiation; TB-IRIS arising in patients starting ART; and the residual increased risk of active TB in patients

396　on ART. Therefore, ongoing research that focusses on the mechanisms by which the two pathogens interact

397　in these circumstances, and identification of possible therapeutic targets, is necessary. Specific priorities

398　include being able to (1) stratify the risks of active TB in order to inform optimal use of systematic screening

399　for active TB or strategies for preventative therapy; (2) to identify opportunities for host directed therapies that

400　treat or reduce the risk of TB-IRIS, or population level interventions to reduce the risk of active TB, such as

401　vitamin D supplementation; and (3) to evaluate the effects of active TB or LTBI on subclinical viral replication

402　and diversification that may promote HIV-1 drug resistance and persistence.

403　The application of whole-genome sequencing and single genome amplification[146] will offer greater depths of

404　resolution to explore the effect of *M. tuberculosis* co-infection on HIV-1 diversity. Likewise, whole-genome

405　sequencing of *M. tuberculosis* is expected to offer more insight into transmission chains[147] in order to assess

406  the impact of HIV-1 on the spread of *M. tuberculosis*, and whether HIV-1 influences sympatric speciation of
407  *M. tuberculosis*[148]. Interestingly, a recent whole-genome sequencing study of *M. tuberculosis* strains in HIV-1
408  infected and uninfected individuals suggested virus-induced changes to bacterial evolution that disrupt the
409  unusually high degree of epitope conservation in *M. tuberculosis*[149].

410  HIV-1, and for the most part *M. tuberculosis,* are exclusively human pathogens, often rendering conventional
411  small models of disease misrepresentative. The recent developments in humanised mouse models for HIV-1
412  may also represent a significant opportunity to study co-infection. Likewise, the use of non-human primates in
413  which the combination of blood sampling and functional imaging offers the opportunity for detailed and
414  well-controlled longitudinal experiments to study co-infection. The prospect of human TB challenge models
415  are also emerging[150]. In addition to the primary goal of developing tools to evaluate *M. tuberculosis* vaccine
416  efficacy, these would offer unprecedented opportunities to identify correlates of protection and to study
417  pathogenesis in co-infected individuals, particularly in the context of ART. These models could enable the
418  assessment of variables other than T cell depletion during co-infection, and explore the effects of chronic
419  inflammation, ageing, smoking, obesity and diabetes. Ultimately, the study of HIV/TB co-infection will also be
420  crucial in the development of effective vaccines for these important pathogens, based on our understanding
421  of how they undermine host defences through their interactions.

**Competing interests statement**

428  The authors declare no competing interests.

**Publisher's note**

430  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional
431  affiliations.

**Author biographies**

433  Lucy C. K. Bell completed medical training at the University of Cambridge and University College London
434  (UCL), during which she completed a PhD, studying the impact of HIV-1 co-infection on immune responses to
435  TB. She is now an academic clinical trainee at Guys' & St Thomas' Hospitals and King's College London, and
436  maintains active research interests in HIV-1, TB and transcriptomics.

437  Mahdad Noursadeghi is a Clinician Scientist and leads a research group in Infection and Immunity at University
438  College London, focusing on HIV-1 and Tuberculosis. They model innate immune host-pathogen interactions
439  in human macrophages, and use molecular profiling of challenge experiments in humans and sampling of
440  tissues at the site of disease in order to understand host-pathogen interactions in vivo.

441  Table of contents blurb

*Text*

Co-infection with *Mycobacterium tuberculosis* is the leading cause of death in HIV-1 infected individuals. In this Review, Bell and Noursadeghi describe the epidemiological associations between the two pathogens, selected interactions of each pathogen with the host and our current understanding of how they affect the pathogenesis of tuberculosis and HIV-1/AIDS in co-infected individuals.

**Subject categories**

Biological sciences / Immunology / Infectious diseases / HIV infections

[URI /631/250/255/1901]

Biological sciences / Immunology / Infectious diseases / Tuberculosis

[URI /631/250/255/1856]

Biological sciences / Microbiology / Virology / Viral pathogenesis

[URI /631/326/596/2555]

Biological sciences / Microbiology / Bacteria / Bacterial pathogenesis

[URI /631/326/41/2531]

Biological sciences / Immunology / Immunological disorders / Immunological deficiency syndromes / HIV infections

[URI /631/250/249/1570/1901]

Health sciences / Pathogenesis / Immunopathogenesis

[URI /692/420/2780]

*Figure legends*

460 **Tables**

461 **Table 1: HIV-1, active tuberculosis (TB) and HIV-1/TB co-infection in 2015[3,4].**

| Global burden of disease | |
|---|---|
| **New HIV-1 infections** | 2.1 million |
| **Individuals living with HIV-1** | 36.7 million |
| **New cases of active TB** | 10.4 million |
| **New cases of MDR-TB** | 480,000 |
| **Individuals with latent TB infection (LTBI)** | 1 in 4 individuals globally |
| **Mortality** | |
| **Deaths attributed to HIV-1** | 1.1 million |
| **Deaths attributed to TB** | 1.8 million |
| **TB case fatality rate** | 17% |
| **Burden of co-infection** | |
| **Cases of active TB among individuals with HIV-1** | 1.14 million |
| **Deaths attributed to HIV-1/TB co-infection** | 400,000 |

462

463 **Figure legends**

464 **Figure 1. HIV-1/TB co-infection increases the risk of active TB and HIV-1 disease progression.**

465 **(A)** The risk of active tuberculosis (TB) increases to 2-5 fold above baseline soon after an individual is infected

466 with HIV-1 during the early and chronic phases of infection. As HIV-1 progresses and causes severe

467 immunodeficiency, the risk of TB is further increased to at least 20-fold greater than the general population.

468 TB risk is accrued with longer times spent at low blood CD4$^+$ T cell counts. Moreover, antiretroviral therapy

469 (ART) for HIV-1 does not fully restore the risk to baseline. There remains >4 fold increased rates of active TB

470 even once CD4$^+$ T cell counts have reconstituted. **(B)** Incident *Mycobacterium tuberculosis* co-infection in

471 HIV-1 infected people increases HIV-1 replication and consequently viral diversity. It may also potentiate

472 chronic immune activation, accelerating the progression of HIV-1 disease.

473 **Figure 2. HIV-1 Nef may compromise host control of *Mycobacterium tuberculosis* by inhibition of**
474 **bacterial phagocytosis and autophagic clearance of phagosomal cargo.**

475 Macrophage control of *M. tuberculosis* is thought to be mediated by bacterial phagocytosis and the clearance

476 of *M. tuberculosis* containing phagosomes that fail to undergo phagolysosomal fusion via the autophagy

477 pathway. HIV-1 co-infection can undermine this mechanism of host defence at multiple levels. *M. tuberculosis*

478 clearance by this pathway is also dependent on vitamin D and augmented by Th1 responses through the action

479 of IFN$\gamma$. Deficiency of IFN$\gamma$ responses owing to depletion of *M. tuberculosis* reactive Th1 cells in progressive

480 HIV-1 disease is thought to be the canonical mechanism by which HIV-1 compromises host defence against

481 *M. tuberculosis*. In addition, the HIV-1 Nef accessory protein reduces macrophage phagocytic capacity by

482 inhibiting AP-1-mediated endosomal recycling that is needed to form nascent phagosomes. Autophagosome

483 assembly is increased in HIV-1 infected macrophages, but their maturation and clearance function by fusion

484 with lysosomes is attenuated by the interaction of HIV-1 Nef with the autophagy related gene, Beclin-1.

485 Interestingly, vitamin D supplementation may overcome this inhibition of autophagosome maturation to

486 improve both *M. tuberculosis* clearance, and HIV-1 restriction by autophagy.

487 **Figure 3. High bacillary burden, T cell recovery and HIV-1-induced failure of immunoregulation drive**
488 **TB immune reconstitution inflammatory syndrome (TB-IRIS).**

489 Exaggerated pro-inflammatory responses that are normally derived from innate immune activation of myeloid

490 cells are the dominant feature of TB-IRIS, and T cell derived IFN$\gamma$ responses are known to augment innate

491 immune responses by macrophages (A). Therefore the most likely model for exaggerated macrophage derived

492 inflammation in TB-IRIS is the combined effects of high bacillary burden in immunocompromised patients

493 before the onset of antiretroviral therapy (ART) **(B)** and recirculation of *Mycobacterium tuberculosis* reactive T

494 cells after ART initiation **(C)**. Although ART effectively blocks cell-cell propagation of the virus, the treatment

495 does not clear integrated HIV-1 provirus in macrophages which continue to express HIV-1 proteins. **(D)** In this

496 context HIV-1 inhibition of macrophage IL10 responses to *M. tuberculosis* may also contribute to exaggerated

497 inflammatory responses by a failure of immunoregulation **(D)**. CC, chemokines.

498 **Figure 4. Tuberculosis increases HIV-1 replication and propagation through innate immune signalling**
499 **pathways, proinflammatory cytokines and failure of immunoregulation.**

500 **(A)** Innate immune signalling pathways in macrophages can increase HIV-1 transcription through activation of

501 NFkB, C/EBP, CREB/ATF and NFAT transcription factors. The host cell response to innate immune activation

502 by *Mycobacterium tuberculosis* leads to the production of a range of proinflammatory cytokines and

503 chemokines. These drive the local recruitment of T cells as part of a prototypic cell mediated immune response

504 **(B)**. The accumulation of activated T cells provides a population of cells permissive to HIV-1 and allows for

505  rapid virus propagation by direct cell-cell spread **(C)**. The pro-inflammatory cytokines also serve to promote

506  transctivation of virus replication through the action of NFkB and NFAT transcription factors **(D)**. HIV-1

507  attenuation of IL10 responses to *M. tuberculosis* favours the virus by reducing IL10 mediated inhibition of HIV-

508  1 transcription via C/EBPβ and by promoting pro-inflammatory responses through a failure of

509  immunoregulation **(E)**. Although *M. tuberculosis* induces type1 IFN responses in macrophages, which would

510  be expected to promote an antiviral state, any autocrine or paracrine inhibition of HIV-1 replication is transient

511  **(F)**. Recent data has emerged to show that *M. tuberculosis* causes macrophage polyploidy through activation

512  of the cell cycle coupled to cytokinesis failure **(G)**. G1-like macrophages are more permissive to HIV-1.

513  Whether, *M. tuberculosis* induction of multinucleated giant cells further increases the HIV-1 permissive host

514  cellular niche, merits further investigation. CC, chemokines.

515

## References

517    1.    Korber, B. *et al.* Timing the ancestor of the HIV-1 pandemic strains. *Science* **288,** 1789–1796 (2000).

518    2.    Russell, D. G. Who puts the tubercle in tuberculosis? *Nat. Rev. Microbiol.* **5,** 39–47 (2007).

519    3.    UNAIDS. *Global AIDS update 2016.* (2016).

520    4.    World Health Organisation. *Global tuberculosis report 2016.* (2016).

521    5.    Dolan, K. *et al.* Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *Lancet*
522      *Lond. Engl.* **388,** 1089–1102 (2016).

523    6.    Corbett, E. L. *et al.* Risk factors for pulmonary mycobacterial disease in South African gold miners. A
524      case-control study. *Am. J. Respir. Crit. Care Med.* **159,** 94–99 (1999).

525    7.    Mesfin, Y. M., Hailemariam, D., Biadglign, S. & Kibret, K. T. Association between HIV/AIDS and Multi-
526      Drug Resistance Tuberculosis: A Systematic Review and Meta-Analysis. *PLoS ONE* **9,** (2014).

527    8.    Gupta, R. K., Lucas, S. B., Fielding, K. L. & Lawn, S. D. Prevalence of tuberculosis in post-mortem
528      studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-
529      analysis. *AIDS Lond. Engl.* **29,** 1987–2002 (2015).

530    **Metanalysis including greater than 3200 autopsies from low and middle income countries which**
531    **estimated that TB was the cause of death in 37.2% of HIV-1 infected individuals.**

532    9.    Sonnenberg, P. *et al.* How soon after infection with HIV does the risk of tuberculosis start to increase? A
533      retrospective cohort study in South African gold miners. *J. Infect. Dis.* **191,** 150–158 (2005).

534    10.    Getahun, H., Gunneberg, C., Granich, R. & Nunn, P. HIV infection-associated tuberculosis: the
535      epidemiology and the response. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **50 Suppl 3,** S201-207
536      (2010).

537    11.    Lawn, S. D., Evans, A. J., Sedgwick, P. M. & Acheampong, J. W. Pulmonary tuberculosis: radiological
538      features in west Africans coinfected with HIV. *Br. J. Radiol.* **72,** 339–344 (1999).

539    12.    Naing, C., Mak, J. W., Maung, M., Wong, S. F. & Kassim, A. I. B. M. Meta-analysis: the association
540      between HIV infection and extrapulmonary tuberculosis. *Lung* **191,** 27–34 (2013).

541    13.    Gilks, C. F. *et al.* Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients
542      presenting to the acute medical services in Nairobi. *AIDS Lond. Engl.* **4,** 981–985 (1990).

543    14.    Goletti, D. *et al.* Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. *J.*
544    *Immunol. Baltim. Md 1950* **157,** 1271–1278 (1996).

545    15.    Marais, S., Meintjes, G., Lesosky, M., Wilkinson, K. A. & Wilkinson, R. J. Interleukin-17 mediated
546    differences in the pathogenesis of HIV-1-associated tuberculous and cryptococcal meningitis. *AIDS*
547    *Lond. Engl.* **30,** 395–404 (2016).

548    16.    Collins, K. R. *et al.* Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of
549    Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. *J. Virol.* **76,** 1697–1706
550    (2002).

551    17.    Lawn, S. D. *et al.* Anatomically compartmentalized human immunodeficiency virus replication in HLA-
552    DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. *J. Infect. Dis.* **184,**
553    1127–1133 (2001).

554    18.    Nakata, K. *et al.* Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in
555    the lung. *Am. J. Respir. Crit. Care Med.* **155,** 996–1003 (1997).

556    19.    Toossi, Z. *et al.* Systemic immune activation and microbial translocation in dual HIV/TB infected subjects.
557    *J. Infect. Dis.* (2013). doi:10.1093/infdis/jit092

558    20.    Meng, Q. *et al.* Immune Activation at Sites of HIV/TB Co-Infection Contributes to the Pathogenesis of
559    HIV-1 Disease. *PloS One* **11,** e0166954 (2016).

560    21.    Sullivan, Z. A., Wong, E. B., Ndung'u, T., Kasprowicz, V. O. & Bishai, W. R. Latent and Active
561    Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV. *EBioMedicine* **2,**
562    334–340 (2015).

563    22.    Mellors, J. W. *et al.* Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
564    *Ann. Intern. Med.* **126,** 946–954 (1997).

565    23.    Deeks, S. G. *et al.* Immune activation set point during early HIV infection predicts subsequent CD4+ T-
566    cell changes independent of viral load. *Blood* **104,** 942–947 (2004).

567    24.    Whalen, C. *et al.* Accelerated course of human immunodeficiency virus infection after tuberculosis. *Am.*
568    *J. Respir. Crit. Care Med.* **151,** 129–135 (1995).

569    25.    Badri, M., Ehrlich, R., Wood, R., Pulerwitz, T. & Maartens, G. Association between tuberculosis and HIV
570    disease progression in a high tuberculosis prevalence area. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union*
571    *Tuberc. Lung Dis.* **5,** 225–232 (2001).

572 26. Kabali, C. *et al.* Increased mortality associated with treated active tuberculosis in HIV-infected adults in

573     Tanzania. *Tuberc. Edinb. Scotl.* **93,** 461–466 (2013).

574 27. Nunes-Alves, C. *et al.* In search of a new paradigm for protective immunity to TB. *Nat. Rev. Microbiol.*

575     **12,** 289–299 (2014).

576 28. Lahouassa, H. *et al.* SAMHD1 restricts the replication of human immunodeficiency virus type 1 by

577     depleting the intracellular pool of deoxynucleoside triphosphates. *Nat. Immunol.* **13,** 223–228 (2012).

578 29. Calantone, N. *et al.* Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis

579     of infected T cells. *Immunity* **41,** 493–502 (2014).

580 30. Mlcochova, P. *et al.* A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. *EMBO*

581     *J.* e201696025 (2017). doi:10.15252/embj.201696025

582 **HIV-1 was able to productively infect macrophages in non-replicative cell cycle during which SAMHD1**
583 **is inactivated, providing a niche which HIV-1 has exploited without a countermeasure for SAMHD1**
584 **restriction.**

585 31. Jambo, K. C. *et al.* Small alveolar macrophages are infected preferentially by HIV and exhibit impaired

586     phagocytic function. *Mucosal Immunol.* (2014). doi:10.1038/mi.2013.127

587 **Direct evidence was identified for productive HIV-1 infection in up to 5% of alveolar macrophages in**
588 **bronchoalveolar lavage specimens by RNA fluorescence in situ hybridisation, and further**
589 **assessments showed that these cells exhibited impaired phagocytosis of reported beads.**

590 32. Honeycutt, J. B. *et al.* Macrophages sustain HIV replication in vivo independently of T cells. *J. Clin.*

591     *Invest.* (2016). doi:10.1172/JCI84456

592 **HIV-1 was able to sustain long term productive infection in vivo, in a mouse model with human myeloid**
593 **cells , but without T cells, indicating that macrophages are sufficient to support chronic HIV-1 infection.**

594 33. Igarashi, T. *et al.* Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques

595     after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1

596     chimera (SHIV): Implications for HIV-1 infections of humans. *Proc. Natl. Acad. Sci. U. S. A.* **98,** 658–663

597     (2001).

598 34. Cribbs, S. K., Lennox, J., Caliendo, A. M., Brown, L. A. & Guidot, D. M. Healthy HIV-1-infected individuals

599     on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. *AIDS Res. Hum.*

600     *Retroviruses* **31,** 64–70 (2015).

601 35. Honeycutt, J. B. *et al.* HIV persistence in tissue macrophages of humanized myeloid-only mice during

602     antiretroviral therapy. *Nat. Med.* **23,** 638–643 (2017).

603   36.   Churchill, M. J., Deeks, S. G., Margolis, D. M., Siliciano, R. F. & Swanstrom, R. HIV reservoirs: what,
604           where and how to target them. *Nat. Rev. Microbiol.* **14,** 55–60 (2016).

605   37.   Lorenzo-Redondo, R. *et al.* Persistent HIV-1 replication maintains the tissue reservoir during therapy.
606           *Nature* **530,** 51–56 (2016).

607   38.   Boritz, E. A. *et al.* Multiple Origins of Virus Persistence during Natural Control of HIV Infection. *Cell* **166,**
608           1004–1015 (2016).

609   39.   Churchill, M. J. *et al.* Use of laser capture microdissection to detect integrated HIV-1 DNA in
610           macrophages and astrocytes from autopsy brain tissues. *J. Neurovirol.* **12,** 146–152 (2006).

611   40.   McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious disease.
612           *Nat. Rev. Immunol.* **15,** 87–103 (2015).

613   41.   Stacey, A. R. *et al.* Induction of a striking systemic cytokine cascade prior to peak viremia in acute human
614           immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute
615           hepatitis B and C virus infections. *J. Virol.* **83,** 3719–3733 (2009).

616   42.   Beignon, A.-S. *et al.* Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor–
617           viral RNA interactions. *J. Clin. Invest.* **115,** 3265–3275 (2005).

618   43.   Berg, R. K. *et al.* Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing
619           of secondary-structured RNA. *PloS One* **7,** e29291 (2012).

620   44.   Gringhuis, S. I. *et al.* HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after
621           sensing of abortive HIV-1 RNA by the host helicase DDX3. *Nat. Immunol.* **18,** 225–235 (2017).

622   45.   Gao, D. *et al.* Cyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses.
623           *Science* **341,** 903–906 (2013).

624   46.   Yoh, S. M. *et al.* PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1. *Cell*
625           **161,** 1293–1305 (2015).

626   47.   Jakobsen, M. R. *et al.* IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1
627           replication. *Proc. Natl. Acad. Sci. U. S. A.* **110,** E4571-4580 (2013).

628   48.   Sandler, N. G. *et al.* Type I interferon responses in rhesus macaques prevent SIV infection and slow
629           disease progression. *Nature* **511,** 601–605 (2014).

630  49.  Doyle, T., Goujon, C. & Malim, M. H. HIV-1 and interferons: who's interfering with whom? *Nat. Rev.*
631      *Microbiol.* **13,** 403–413 (2015).

632  50.  Rasaiyaah, J. *et al.* HIV-1 evades innate immune recognition through specific cofactor recruitment.
633      *Nature* **503,** 402–405 (2013).

634  51.  Tsang, J. *et al.* HIV-1 infection of macrophages is dependent on evasion of innate immune cellular
635      activation. *AIDS Lond. Engl.* **23,** 2255–2263 (2009).

636  52.  Douek, D. C., Roederer, M. & Koup, R. A. Emerging concepts in the immunopathogenesis of AIDS.
637      *Annu. Rev. Med.* **60,** 471–484 (2009).

638  53.  Muenchhoff, M. *et al.* Nonprogressing HIV-infected children share fundamental immunological features
639      of nonpathogenic SIV infection. *Sci. Transl. Med.* **8,** 358ra125 (2016).

640  54.  Brenchley, J. M. *et al.* Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral
641      infections. *Blood* **112,** 2826–2835 (2008).

642  55.  Stieh, D. J. *et al.* Th17 Cells Are Preferentially Infected Very Early after Vaginal Transmission of SIV in
643      Macaques. *Cell Host Microbe* **19,** 529–540 (2016).

644  56.  Doitsh, G. *et al.* Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. *Nature* **advance**
645      **online publication,** (2013).

646  57.  Monroe, K. M. *et al.* IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected
647      with HIV. *Science* **343,** 428–432 (2014).

648  58.  Galloway, N. L. K. *et al.* Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of
649      Lymphoid-Tissue-Derived CD4 T Cells. *Cell Rep.* **12,** 1555–1563 (2015).

650  59.  Doitsh, G. & Greene, W. C. Dissecting How CD4 T Cells Are Lost During HIV Infection. *Cell Host Microbe*
651      **19,** 280–291 (2016).

652  60.  Cooper, A. *et al.* HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral
653      integration. *Nature* **498,** 376–379 (2013).

654  61.  Deeks, S. G. HIV Infection, Inflammation, Immunosenescence, and Aging. *Annu. Rev. Med.* **62,** 141–
655      155 (2011).

656  62.  Khaitan, A. & Unutmaz, D. Revisiting Immune Exhaustion During HIV Infection. *Curr. HIV/AIDS Rep.* **8,**
657      4–11 (2011).

658    63.  Beyer, M. *et al.* Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic

659         viral infection. *Nat. Immunol.* **17,** 593–603 (2016).

660    **Evidence from HIV-1 infected patients and the chronic LCMV mouse infection model indicates that**

661    **persistently elevated TNF levels can inhibit helper T cell function by upregulating expression of**

662    **inhibitory molecules such as PD1, suggesting a mechanism by which chronic inflammation can lead**

663    **to immunodeficiency.**

664    64.  Jolly, C., Kashefi, K., Hollinshead, M. & Sattentau, Q. J. HIV-1 cell to cell transfer across an Env-induced,

665         actin-dependent synapse. *J. Exp. Med.* **199,** 283–293 (2004).

666    65.  Jolly, C. Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction

667         factors. *Virology* **411,** 251–259 (2011).

668    66.  Boullé, M. *et al.* HIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple

669         Infections per Cell. *PLoS Pathog.* **12,** e1005964 (2016).

670    67.  Baxter, A. E. *et al.* Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. *Cell Host*

671         *Microbe* **16,** 711–721 (2014).

672    68.  Schnappinger, D. *et al.* Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages.

673         *J. Exp. Med.* **198,** 693–704 (2003).

674    **Transcriptional profiling of *M. tuberculosis* isolated from phagosomes compared to bacteria grown in**

675    **broth culture revealed that in response to phagosomal uptake and the effects of host IFNγ or inducible**

676    **nitric oxide synthase, the bacteria upregulate iron scavenging systems, expression of dormancy**

677    **related genes and genes that support anaerobic respiration.**

678    69.  Peddireddy, V., Doddam, S. N. & Ahmed, N. Mycobacterial Dormancy Systems and Host Responses in

679         Tuberculosis. *Front. Immunol.* **8,** (2017).

680    70.  Simeone, R. *et al.* Phagosomal Rupture by Mycobacterium tuberculosis Results in Toxicity and Host Cell

681         Death. *PLoS Pathog.* **8,** (2012).

682    71.  Volkman, H. E. *et al.* Tuberculous granuloma induction via interaction of a bacterial secreted protein with

683         host epithelium. *Science* **327,** 466–469 (2010).

684    72.  Mishra, B. B. *et al.* Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC

685         inflammasome. *Cell. Microbiol.* **12,** 1046–1063 (2010).

686    73.  Davis, J. M. & Ramakrishnan, L. The Role of the Granuloma in Expansion and Dissemination of Early

687         Tuberculous Infection. *Cell* **136,** 37–49 (2009).

688    74.   Kleinnijenhuis, J., Oosting, M., Joosten, L. A. B., Netea, M. G. & Van Crevel, R. Innate immune
689          recognition of Mycobacterium tuberculosis. *Clin. Dev. Immunol.* **2011,** 405310 (2011).

690    75.   Watson, R. O. *et al.* The Cytosolic Sensor cGAS Detects Mycobacterium tuberculosis DNA to Induce
691          Type I Interferons and Activate Autophagy. *Cell Host Microbe* **17,** 811–819 (2015).

692    76.   Liu, P. T. *et al.* Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.
693          *Science* **311,** 1770–1773 (2006).

694    77.   Berry, M. P. R. *et al.* An interferon-inducible neutrophil-driven blood transcriptional signature in human
695          tuberculosis. *Nature* **466,** 973–977 (2010).

696    78.   Mayer-Barber, K. D. *et al.* Host-directed therapy of tuberculosis based on interleukin-1 and type I
697          interferon crosstalk. *Nature* **511,** 99–103 (2014).

698    79.   Manzanillo, P. S., Shiloh, M. U., Portnoy, D. A. & Cox, J. S. Mycobacterium Tuberculosis Activates the
699          DNA-Dependent Cytosolic Surveillance Pathway within Macrophages. *Cell Host Microbe* **11,** 469–480
700          (2012).

701    80.   Wassermann, R. *et al.* Mycobacterium tuberculosis Differentially Activates cGAS- and Inflammasome-
702          Dependent Intracellular Immune Responses through ESX-1. *Cell Host Microbe* **17,** 799–810 (2015).

703    **Inflammasome activation leading to secretion of active IL1β and induction of type 1 IFNs by**
704    **macrophages infected with *M. tuberculosis* is dependent on the mycobacterial ESX1 secretion system,**
705    **and specific targeting of EsxA secretion attenuated induction of IFNs but not activation of the**
706    **inflammasome.**

707    81.   Elkington, P. *et al.* MMP-1 drives immunopathology in human tuberculosis and transgenic mice. *J. Clin.*
708          *Invest.* (2011). doi:10.1172/JCI45666

709    82.   Comas, I. *et al.* Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved.
710          *Nat. Genet.* **42,** 498–503 (2010).

711    83.   Coscolla, M. *et al.* M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and
712          Identifies Rare Variable TB Antigens. *Cell Host Microbe* **18,** 538–548 (2015).

713    84.   Al-Muhsen, S. & Casanova, J.-L. The genetic heterogeneity of mendelian susceptibility to mycobacterial
714          diseases. *J. Allergy Clin. Immunol.* **122,** 1043-1051; quiz 1052-1053 (2008).

715    85.   Bell, L. C. K. *et al.* In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. *PLOS*
716          *Pathog* **12,** e1005469 (2016).

717  **Genome-wide transcriptional profiling of biopsies from the site of the tuberculin skin test to make**
718  **molecular and systems level assessments of human immune responses to a standardised**
719  **mycobacterial challenge revealed deficient IL10 responses in HIV-1 infected patients before severe**
720  **immunodeficiency, preserved type 1 IFN responses in HIV-1 infected patients with severe**
721  **immunodeficiency, and exaggerated Th2 responses during unmasking TB-IRIS after antiretroviral**
722  **therapy.**

723  86.  Kalsdorf, B. *et al.* HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. *Am. J.*
724      *Respir. Crit. Care Med.* **180,** 1262–1270 (2009).

725  87.  Geldmacher, C. *et al.* Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T
726      cells after HIV-1 infection. *J. Exp. Med.* **207,** 2869–2881 (2010).

727  **Preferential depletion of *M. tuberculosis* reactive CD4 T cells which produced more IL2, were more**
728  **permissive to HIV-1 infection, suggested that HIV-1 targeting of these cells may contribute to increased**
729  **risk of TB in early HIV-1 infection, before generalised T cell depletion.**

730  88.  Cruz, A. *et al.* Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after
731      infection with Mycobacterium tuberculosis. *J. Exp. Med.* **207,** 1609–1616 (2010).

732  89.  Nandi, B. & Behar, S. M. Regulation of neutrophils by interferon-γ limits lung inflammation during
733      tuberculosis infection. *J. Exp. Med.* **208,** 2251–2262 (2011).

734  90.  Treerat, P. *et al.* Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878
735      infection. *Mucosal Immunol.* **10,** 1069–1081 (2017).

736  91.  Kim, C. J. *et al.* A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal
737      immunopathogenesis. *Mucosal Immunol.* **5,** 670–680 (2012).

738  92.  Saeidi, A. *et al.* Functional role of mucosal-associated invariant T cells in HIV infection. *J. Leukoc. Biol.*
739      **100,** 305–314 (2016).

740  93.  Jiang, J. *et al.* Mucosal-associated invariant T-cell function is modulated by programmed death-1
741      signaling in patients with active tuberculosis. *Am. J. Respir. Crit. Care Med.* **190,** 329–339 (2014).

742  94.  Gupta, A., Wood, R., Kaplan, R., Bekker, L.-G. & Lawn, S. D. Tuberculosis incidence rates during 8 years
743      of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
744      *PloS One* **7,** e34156 (2012).

745  95.  Heather, J. M. *et al.* Dynamic Perturbations of the T-Cell Receptor Repertoire in Chronic HIV Infection
746      and following Antiretroviral Therapy. *Front. Immunol.* **6,** (2016).

*References*

**Comprehensive TCR repertoire analysis by next generation sequencing of samples of HIV-1 infected patients showed incomplete reconstitution of the T cell repertoire 3 months after effective antiretroviral therapy.**

96. Cosgrove, C. *et al.* Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. *Blood* **121,** 951–961 (2013).

97. Cambier, C. J. *et al.* Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. *Nature* **505,** 218–222 (2014).

98. Roca, F. J. & Ramakrishnan, L. TNF Dually Mediates Resistance and Susceptibility to Mycobacteria via Mitochondrial Reactive Oxygen Species. *Cell* **153,** 521–534 (2013).

99. Alonso, S., Pethe, K., Russell, D. G. & Purdy, G. E. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. *Proc. Natl. Acad. Sci.* **104,** 6031–6036 (2007).

100. Gutierrez, M. G. *et al.* Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages. *Cell* **119,** 753–766 (2004).

101. Mazzolini, J. *et al.* Inhibition of phagocytosis in HIV-1-infected macrophages relies on Nef-dependent alteration of focal delivery of recycling compartments. *Blood* **115,** 4226–4236 (2010).

**Inhibition of macrophage phagocytic uptake by the effect of HIV-1 Nef accessory protein on AP-1 mediated recycling of endosomes required for phagosome formation.**

102. Toossi, Z., Liu, S., Wu, M., Mayanja-Kizza, H. & Hirsch, C. S. Short Communication: Circulating Plasma HIV-1 Viral Protein R in Dual HIV-1/Tuberculosis Infection. *AIDS Res. Hum. Retroviruses* **30,** 644–647 (2014).

103. Fujii, Y., Otake, K., Tashiro, M. & Adachi, A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. *FEBS Lett.* **393,** 93–96 (1996).

104. Kyei, G. B. *et al.* Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. *J. Cell Biol.* **186,** 255–268 (2009).

**Induction of autophagosome formation in HIV-1 infected macrophages, wherein HIV-1 Nef mediated autophagosome maturation supports HIV-1 replication but counteracts autophagic degradation of the virus and might be expected to inhibit autophagic clearance of mycobacteria.**

105. Pathak, S., Wentzel-Larsen, T. & Asjo, B. Effects of in vitro HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages. *Infect.Immun.* **78,** 4022–4032 (2010).

776   106. Campbell, G. R. & Spector, S. A. Vitamin D Inhibits Human Immunodeficiency Virus Type 1 and

777         Mycobacterium tuberculosis Infection in Macrophages through the Induction of Autophagy. *PLoS Pathog.*

778         **8,** (2012).

779   107. Martineau, A. R. *et al.* Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in

780         Cape Town, South Africa. *Proc. Natl. Acad. Sci. U. S. A.* **108,** 19013–19017 (2011).

781   108. Patel, N. R. *et al.* HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium

782         tuberculosis. *J. Immunol. Baltim. Md 1950* **179,** 6973–6980 (2007).

783   109. Patel, N. R., Swan, K., Li, X., Tachado, S. D. & Koziel, H. Impaired M. tuberculosis-mediated apoptosis

784         in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. *J. Leukoc. Biol.* **86,** 53–

785         60 (2009).

786   110. Kumawat, K., Pathak, S. K., Spetz, A.-L., Kundu, M. & Basu, J. Exogenous Nef is an inhibitor of

787         Mycobacterium tuberculosis-induced tumor necrosis factor-alpha production and macrophage apoptosis.

788         *J. Biol. Chem.* **285,** 12629–12637 (2010).

789   111. Mahamed, D. *et al.* Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads

790         to serial killing of host cells. *eLife* **6,** e22028 (2017).

791   112. Walker, N. F. *et al.* Doxycycline and HIV infection suppress tuberculosis-induced matrix

792         metalloproteinases. *Am. J. Respir. Crit. Care Med.* **185,** 989–997 (2012).

793   113. Huang, C.-C. *et al.* The effect of HIV-related immunosuppression on the risk of tuberculosis transmission

794         to household contacts. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **58,** 765–774 (2014).

795   114. Bell, L. C. K., Breen, R., Miller, R. F., Noursadeghi, M. & Lipman, M. Paradoxical reactions and immune

796         reconstitution inflammatory syndrome in tuberculosis. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect.*

797         *Dis.* **32,** 39–45 (2015).

798   115. Müller, M. *et al.* Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy

799         for HIV infection: a systematic review and meta-analysis. *Lancet Infect. Dis.* **10,** 251–261 (2010).

800   116. Lai, R. P. J. *et al.* HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is

801         characterized by Toll-like receptor and inflammasome signalling. *Nat. Commun.* **6,** 8451 (2015).

802   **Pro-inflammatory responses in TB-IRIS cases were enriched for innate immune MyD88 and**

803   **inflammasome mediated pathways in myeloid cells suggesting that unregulated recovery of these**

804   **pathways after antiretroviral therapy may be responsible for the pathogenesis of IRIS.**

805    117. Tachado, S. D. *et al.* MyD88-dependent TLR4 signaling is selectively impaired in alveolar macrophages
806            from asymptomatic HIV+ persons. *Blood* **115,** 3606–3615 (2010).

807    118. Tachado, S. D., Li, X., Swan, K., Patel, N. & Koziel, H. Constitutive activation of phosphatidylinositol 3-
808            kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar
809            macrophages from asymptomatic HIV-positive persons in vitro. *J. Biol. Chem.* **283,** 33191–33198 (2008).

810    119. Noursadeghi, M., Katz, D. R. & Miller, R. F. HIV-1 infection of mononuclear phagocytic cells: the case
811            for bacterial innate immune deficiency in AIDS. *Lancet Infect. Dis.* **6,** 794–804 (2006).

812    120. Noursadeghi, M. *et al.* Genome-wide innate immune responses in HIV-1-infected macrophages are
813            preserved despite attenuation of the NF-kappa B activation pathway. *J. Immunol. Baltim. Md 1950* **182,**
814            319–328 (2009).

815    121. Tomlinson, G. S. *et al.* HIV-1 Infection of Macrophages Dysregulates Innate Immune Responses to
816            Mycobacterium tuberculosis by Inhibition of Interleukin-10. *J. Infect. Dis.* **209,** 1055–1065 (2014).

817    **HIV-1 infected macrophages exhibited selective depletion of IL10 responses to *M. tuberculosis***
818    **co-infection, leading to a failure of immunoregulation, exaggerated proinflammatory responses and**
819    **increased HIV-1 replication.**

820    122. Maddocks, S. *et al.* Gene expression in HIV-1/Mycobacterium tuberculosis co-infected macrophages is
821            dominated by M. tuberculosis. *Tuberc. Edinb. Scotl.* **89,** 285–293 (2009).

822    123. Pathak, S., Wentzel-Larsen, T. & Asjö, B. Effects of in vitro HIV-1 infection on mycobacterial growth in
823            peripheral blood monocyte-derived macrophages. *Infect. Immun.* **78,** 4022–4032 (2010).

824    124. Tan, D. B. A. *et al.* TLR2-induced cytokine responses may characterize HIV-infected patients
825            experiencing mycobacterial immune restoration disease. *AIDS Lond. Engl.* **25,** 1455–1460 (2011).

826    125. Tran, H. T. T. *et al.* Modulation of the complement system in monocytes contributes to tuberculosis-
827            associated immune reconstitution inflammatory syndrome. *AIDS Lond. Engl.* **27,** 1725–1734 (2013).

828    126. Toossi, Z. *et al.* Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential
829            mechanisms of viral activation. *J.Acquir.Immune.Defic.Syndr.* **28,** 1–8 (2001).

830    127. Van Lint, C., Bouchat, S. & Marcello, A. HIV-1 transcription and latency: an update. *Retrovirology* **10,** 67
831            (2013).

832    128.  Zhang, Y., Nakata, K., Weiden, M. & Rom, W. N. Mycobacterium tuberculosis enhances human
833           immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. *J. Clin.*
834           *Invest.* **95,** 2324–2331 (1995).

835    129.  Henderson, A. J., Zou, X. & Calame, K. L. C/EBP proteins activate transcription from the human
836           immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. *J. Virol.* **69,** 5337–5344
837           (1995).

838    130.  Ranjbar, S., Jasenosky, L. D., Chow, N. & Goldfeld, A. E. Regulation of Mycobacterium tuberculosis-
839           Dependent HIV-1 Transcription Reveals a New Role for NFAT5 in the Toll-Like Receptor Pathway. *PLoS*
840           *Pathog* **8,** e1002620 (2012).

841    131.  Honda, Y. *et al.* Type I Interferon Induces Inhibitory 16-kD CCAAT/ Enhancer Binding Protein (C/EBP)β,
842           Repressing the HIV-1 Long Terminal Repeat in Macrophages: Pulmonary Tuberculosis Alters C/EBP
843           Expression, Enhancing HIV-1 Replication. *J. Exp. Med.* **188,** 1255–1265 (1998).

844    132.  Gröschel, M. I., Sayes, F., Simeone, R., Majlessi, L. & Brosch, R. ESX secretion systems: mycobacterial
845           evolution to counter host immunity. *Nat. Rev. Microbiol.* **14,** 677–691 (2016).

846    133.  Wang, Y. & Rice, A. P. Interleukin-10 inhibits HIV-1 LTR-directed gene expression in human
847           macrophages through the induction of cyclin T1 proteolysis. *Virology* **352,** 485–492 (2006).

848    134.  Kootstra, N. A., van 't Wout, A., Huisman, H. G., Miedema, F. & Schuitemaker, H. Interference of
849           interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived
850           macrophages. *J. Virol.* **68,** 6967–6975 (1994).

851    135.  Tanaka, N. *et al.* Interleukin-10 Induces Inhibitory C/EBPβ through STAT-3 and Represses HIV-1
852           Transcription in Macrophages. *Am. J. Respir. Cell Mol. Biol.* **33,** 406–411 (2005).

853    136.  Duh, E. J., Maury, W. J., Folks, T. M., Fauci, A. S. & Rabson, A. B. Tumor necrosis factor alpha activates
854           human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites
855           in the long terminal repeat. *Proc. Natl. Acad. Sci. U. S. A.* **86,** 5974–5978 (1989).

856    137.  Poli, G., Kinter, A. L. & Fauci, A. S. Interleukin 1 induces expression of the human immunodeficiency
857           virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects
858           by the interleukin 1 receptor antagonist. *Proc. Natl. Acad. Sci. U. S. A.* **91,** 108–112 (1994).

859     138. Poli, G. *et al.* Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells

860          alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional

861          mechanisms. *J. Exp. Med.* **172,** 151–158 (1990).

862     139. Han, X., Becker, K., Degen, H. J., Jablonowski, H. & Strohmeyer, G. Synergistic stimulatory effects of

863          tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type

864          1 and on apoptosis of HIV-1-infected host cells. *Eur. J. Clin. Invest.* **26,** 286–292 (1996).

865     140. Jenkins, S. J. *et al.* Local macrophage proliferation, rather than recruitment from the blood, is a signature

866          of TH2 inflammation. *Science* **332,** 1284–1288 (2011).

867     141. Aziz, A., Soucie, E., Sarrazin, S. & Sieweke, M. H. MafB/c-Maf deficiency enables self-renewal of

868          differentiated functional macrophages. *Science* **326,** 867–871 (2009).

869     142. Schulz, C. *et al.* A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science*

870          **336,** 86–90 (2012).

871     143. Hashimoto, D. *et al.* Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life with

872          Minimal Contribution from Circulating Monocytes. *Immunity* **38,** 792–804 (2013).

873     144. Herrtwich, L. *et al.* DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas. *Cell*

874          **167,** 1264–1280.e18 (2016).

875     145. Lawn, S. D., Kranzer, K. & Wood, R. Antiretroviral Therapy for Control of the HIV-associated Tuberculosis

876          Epidemic in Resource-Limited Settings. *Clin. Chest Med.* **30,** 685–699 (2009).

877     146. Smyth, R. P. & Negroni, M. A step forward understanding HIV-1 diversity. *Retrovirology* **13,** 27 (2016).

878     147. Walker, T. M. *et al.* Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007-

879          12, with whole pathogen genome sequences: an observational study. *Lancet Respir. Med.* **2,** 285–292

880          (2014).

881     148. Fenner, L. *et al.* HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.

882          *PLoS Genet.* **9,** e1003318 (2013).

883     149. Koch, A. S. *et al.* The Influence of HIV on the Evolution of Mycobacterium tuberculosis. *Mol. Biol. Evol.*

884          **34,** 1654–1668 (2017).

885     150. Kaufmann, S. H. E. *et al.* TB biomarkers, TB correlates and human challenge models: New tools for

886          improving assessment of new TB vaccines. *Tuberc. Edinb. Scotl.* **99 Suppl 1,** S8–S11 (2016).

**Figure 1**

**A**



**B**

**Figure 2**

**Figure 3**

**Figure 4**